AbbVie Hit Harder By EU Humira Biosimilars Than Projected

The Q3 earnings call was the first time AbbVie management had to face the masses since the mid-October launch of adalimumab biosimilars across Europe. CEO Gonzalez predicted ex-US Humira revenue erosion of 26%-27% this year, higher than previous estimates.